3.4.22.66: calicivirin
This is an abbreviated version!
For detailed information about calicivirin, go to the full flat file.
Word Map on EC 3.4.22.66
-
3.4.22.66
-
coronavirus
-
sars-cov-2
-
covid-19
-
polyproteins
-
pandemic
-
repurposing
-
outbreak
-
plpro
-
3-chymotrypsin-like
-
papain-like
-
rna-dependent
-
remdesivir
-
ace2
-
mers-cov
-
ramaswamy
-
replicase
-
nonstructural
-
sarma
-
wuhan
-
lopinavir
-
admet
-
anti-sars-cov-2
-
mhv-a59
-
genogroups
-
picornavirus
-
caliciviruses
-
medicine
-
anti-sars
-
norwalk
-
anti-covid-19
-
betacoronavirus
-
sars-coronavirus
-
anti-coronavirus
-
trans-cleavage
-
drug development
-
pp1ab
-
caliciviridae
- 3.4.22.66
- coronavirus
- sars-cov-2
- covid-19
- polyproteins
- pandemic
-
repurposing
-
outbreak
- plpro
-
3-chymotrypsin-like
-
papain-like
-
rna-dependent
- remdesivir
- ace2
- mers-cov
-
ramaswamy
-
replicase
-
nonstructural
-
sarma
-
wuhan
- lopinavir
-
admet
-
anti-sars-cov-2
-
mhv-a59
-
genogroups
- picornavirus
- caliciviruses
- medicine
-
anti-sars
-
norwalk
-
anti-covid-19
- betacoronavirus
-
sars-coronavirus
-
anti-coronavirus
-
trans-cleavage
- drug development
- pp1ab
- caliciviridae
Reaction
endopeptidase with a preference for cleavage when the P1 position is occupied by Glu-/- and the P1' position is occupied by Gly-/- =
Synonyms
3C protease, 3C-like cysteine protease, 3C-like protease, 3C-like proteinase, 3C-like viral protease, 3CL Pro, 3cLpro, 3CP, 3Cpro, C37.001, calicivirus protease, CVP, FCV 3CLpro, NoV 3CLpro, NV 3CLpro, NV protease, NVPro, Pro, PV 3Cpro, Southampton virus 3C-like protease, viral cysteine protease, virus-encoded 3C-like proteinase
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 3.4.22.66 - calicivirin
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
1,6-di(propan-2-yl)-N-(4-[[4-(prop-2-en-1-yl)-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl]methyl]-1,3-thiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
-
compound is predicted to bind to feline calicivirus proteases in a mode similar to that of the authentic substrate, and has the ability to inhibit viral protease activity in vitro and in the cells, and to suppress viral replication in FCV-infected cells. The authentic substrate and anti-FCV compound share a highly conserved binding site
4-(2-aminoethyl)-benzene-sulfonyl fluoride
irreversible inhibition, soluble stable nontoxic alternative to phenylmethylsulfonyl fluoride
benzyl ((3S,6S,9S,Z)-6-(cyclohexylmethyl)-9-formyl-4,7,12-trioxo-11H-5,8,13-triaza-1(4,1)-triazolacyclohexadecaphane-3-yl)carbamate
-
benzyl ((3S,6S,9S,Z)-9-formyl-6-isobutyl-4,7,12-trioxo-11H-5,8,13-triaza-1(4,1)-triazolacyclohexadecaphane-3-yl)carbamate
-
benzyl ((8S,11S,14S,Z)-11-(cyclohexylmethyl)-8-formyl-5,10,13-trioxo-11H-4,9,12-triaza-1(1,4)-triazolacyclopentadecaphane-14-yl)carbamate
-
benzyl [(2S)-1-[[(2S)-3-methyl-1-oxo-1-([(2S)-1-oxo-3-[(1S)-2-oxocyclopentyl]propan-2-yl]amino)butan-2-yl]amino]-3-(naphthalen-1-yl)-1-oxopropan-2-yl]carbamate
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(sulfinooxy)propan-2-yl]-L-valinamide
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
-
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
-
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
-
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
-
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
benzyl [(2S)-1-[[(2S)-3-methyl-1-oxo-1-([(2S)-1-oxo-3-[(1S)-2-oxocyclopentyl]propan-2-yl]amino)butan-2-yl]amino]-3-(naphthalen-1-yl)-1-oxopropan-2-yl]carbamate
-
tripeptidyl compound, potent antiviral activities against both feline coronavirus strain WSU-79-1146 and feline calicivirus strain Urbana. Treatment of coronavirus-infected mice with the compound at 100 mg/kg results in a significant reduction in liver virus titers
benzyl [(2S)-1-[[(2S)-3-methyl-1-oxo-1-([(2S)-1-oxo-3-[(1S)-2-oxocyclopentyl]propan-2-yl]amino)butan-2-yl]amino]-3-(naphthalen-1-yl)-1-oxopropan-2-yl]carbamate
-
tripeptidyl compound, potent antiviral activities against both feline coronavirus strain WSU-79-1146 and feline calicivirus strain Urbana. Treatment of coronavirus-infected mice with the compound at 100 mg/kg results in a significant reduction in liver virus titers
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(sulfinooxy)propan-2-yl]-L-valinamide
-
dipeptidyl compound, statistically significant reduction in the viral load in the liver of virus-infected mice is consistently observed
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(sulfinooxy)propan-2-yl]-L-valinamide
-
dipeptidyl compound, statistically significant reduction in the viral load in the liver of virus-infected mice is consistently observed
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
-
not inhibited by Mg2+, Ca2+, 0.01 mM iodoacetate nor 0.01 mM iodoacetamide
-
additional information
-
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
-
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
-
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
-
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
-
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-
additional information
-
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
-